What is claimed is:

1. A solid composition comprising

(1) a compound, or a pharmaceutically acceptable salt thereof, in an amorphous form,

(2) a pharmaceutically acceptable hydrophilic polymer; and

(3) optionally a pharmaceutically acceptable surfactant,

wherein said compound is selected from the group consisting of:

dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-((2S,5S)-1-(4-*tert*-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate (Compound I_A),

methyl [(2S)-1-{(2S)-2-[4-(4-{5-(4-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)-1-[6-(piperidin-1-yl)pyridin-3-yl]-1H-pyrrol-2-yl}phenyl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate (Compound I_B),

methyl {(2*S*,3*R*)-1-[(2*S*)-2-{6-[(2*R*,5*R*)-1-(4-*tert*-butylphenyl)-5-(2-{(2*S*)-1-[*N*-(methoxycarbonyl)-*O*-methyl-L-threonyl]pyrrolidin-2-yl}-1*H*-benzimidazol-6-yl)pyrrolidin-2-yl]-1*H*-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate (Compound I_C), and

methyl {(2S)-1-[(2S)-2-{5-[(2R,5R)-1-[2,5-difluoro-4-(trifluoromethyl)phenyl]-5-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-benzimidazol-5-yl}pyrrolidin-2-yl]-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I_D).

2. The composition of claim 1, comprising a solid dispersion which includes:

(1) said compound or salt thereof, and

(2) said polymer.

3. The composition of claim 2, wherein said polymer has a T_g of at least 50 °C.

4. The composition of claim 3, further comprising said surfactant.

5. The composition of claim 4, wherein said solid dispersion comprises said surfactant.

6. The composition of claim 4, wherein said polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.

7. The composition of claim 4, wherein said polymer is copovidone.

8. The composition of claim 7, wherein said surfactant is D-alpha-tocopheryl polyethylene glycol 1000 succinate.

9. The composition of claim 7, wherein said surfactant is a combination of D-alpha-tocopheryl polyethylene glycol 1000 succinate and propylene glycol monolaurate.

10. The composition of claim 7, wherein said surfactant is sorbitan mono laurate.

11. The composition of claim 4, wherein said solid dispersion is an amorphous solid dispersion.

12. The composition of claim 4, where said solid dispersion is a solid solution which comprises said surfactant.

13. The composition of claim 1, further comprising another anti-HCV agent.

14. The composition of claim 1, further comprising an HCV protease inhibitor.

15. The composition of claim 1, further comprising an HCV polymerase inhibitor.

16. The composition of claim 4, wherein said compound is Compound I_A.

17. The composition of claim 4, wherein said compound is Compound I_B.

18. The composition of claim 4, wherein said compound is Compound I_C.

19. The composition of claim 4, wherein said compound is Compound I_D.

20. A process of making the composition of claim 1, comprising dissolving said compound or salt in a solvent.

21. The process of claim 20, wherein said solvent is said polymer.


22. A method of treating HCV comprising administering the composition of claim 1 to a patient in need thereof.

23. The method of claim 22, comprising administering another anti-HCV agent to said patient.


What is claimed is:

1. A solid composition comprising

(1) dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate



(



),

or a pharmaceutically acceptable salt thereof, in an amorphous form;

(2) a pharmaceutically acceptable hydrophilic polymer; and

(3) a pharmaceutically acceptable surfactant.

2. The composition of claim 1, comprising a solid dispersion which includes:

(1) said dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate, or said pharmaceutically acceptable salt thereof,

(2) said polymer, and

(3) said surfactant.

3. The composition of claim 2, wherein said polymer has a T_g of at least 50° C.

4. The composition of claim 3, wherein said surfactant has a HLB value of at least 10.

5. The composition of claim 4, further comprising another surfactant having a HLB value of below 10.

6. The composition of claim 3, wherein said solid dispersion is an amorphous solid dispersion which further comprises said surfactant.

7. The composition of claim 3, wherein said polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.

8. The composition of claim 2, wherein said polymer is copovidone.

9. The composition of claim 8, wherein said surfactant is D-alpha-tocopheryl polyethylene glycol 1000 succinate.

10. The composition of claim 8, wherein said surfactant is sorbitan mono laurate.

11. The composition of claim 8, wherein said solid dispersion is an amorphous solid dispersion.

12. The composition of claim 8, where said solid dispersion is a solid solution which comprises said surfactant.

13. The composition of claim 1, further comprising another anti-HCV agent.

14. The composition of claim 1, further comprising an HCV protease inhibitor.

15. The composition of claim 1, further comprising an HCV polymerase inhibitor.

16. The composition of claim 1, further comprising telaprevir or boceprevir.

17. The composition of claim 1, further comprising an anti-HCV agent selected from the group consisting of ITMN-191, BI-201335, VBY-376, VX-500, PHX-B, ACH-1625, IDX136, IDX316, VX-813, SCH 900518, TMC-435, ITMN-191, MK-7009, IDX-PI, BI-201335, R7128, MK-3281, PF-868554, PF-4878691, IDX-184, IDX-375, PPI-461, BILB-1941, GS-9190, BMS-790052, ABT-333, and ABT-072.

18. The composition of claim 1, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

19. The composition of claim 6, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

20. The composition of claim 11, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.

21. The composition of claim 12, wherein said composition comprises at least two pharmaceutically acceptable surfactants, one having an HLB value of at least 10 and the other having an HLB value of below 10.